inr101
Small moleculeexperimental
Clinical trial activity
3 trials · 5 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
3
Phase 3
2
Phase 4
0
Earliest trial started May 23, 2024 (NCT06472531)
Timeline
Indications
Mechanism of action
- Glutamate carboxypeptidase IIBINDING AGENT
FOLH1 binding agent
Chemistry & pharmacology
- Payload
- unclear
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06922929 | Phase 3 | Apr 30, 2025 | Fudan University, Government of China |
| NCT06922903 | Phase 3 | Apr 30, 2025 | Fudan University, Government of China |
| NCT06472531 | Phase 1/Phase 2 (Phase 2) | May 23, 2024 | Capital Medical University, Chinese Academy of Medical Sciences, Government of China, Peking University |
Showing 3 of 3 trials
Page 1 / 1
Organizations
Research & Development (5)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Government of China | Government | 3 | 3 | 2 | 2024 |
| Fudan University | Academic/Hospital | 2 | 0 | 1 | 2025 |
| Capital Medical University | Academic/Hospital | 1 | 0 | 1 | 2024 |
| Chinese Academy of Medical Sciences | Academic/Hospital | 1 | 0 | 1 | 2024 |
| Peking University | Academic/Hospital | 1 | 0 | 1 | 2024 |
5 organizations
Page 1 / 1